In vitro development of three-dimensional (3D) human cardiomyocyte (CM) tissues derived
from human induced pluripotent stem cells (iPSCs) has long been desired in tissue …

Although engineered cardiac tissues (ECTs) derived from induced pluripotent stem cells (iPSCs)
are promising for myocardial regenerative therapy, the appropriate ratio of …

Drug efficacy assessment without using animals is important for development of cardiac
fibrosis treatment. In this study, potential anti-fibrotic drugs were screened in a model of …

Background Clinical effectiveness of autologous skeletal cell‐patch implantation for nonischemic
dilated cardiomyopathy has not been clearly elucidated in clinical settings. This clinical …

Background Transplantation of skeletal myoblast sheets is a promising strategy for the
treatment of heart failure, and its therapeutic effects have already been proven in both animal …

An in vitro drug-induced cardiotoxicity assay is a critical step in drug discovery for clinical
use. The use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is …

Despite major therapeutic advances, heart failure, as a non-communicable disease, remains
a life-threatening disorder, with 26 million patients worldwide, causing more deaths than …

Transplantation of cardiomyocytes (CMs) derived from human induced pluripotent stem cells
(hiPSC-CMs) is a promising treatment for heart failure, but residual undifferentiated hiPSCs …

We evaluated the cardiac function recovery following skeletal myoblast cell-sheet transplantation
and the long-term outcomes after applying this treatment in 23 patients with ischemic …

Heart failure following myocardial infarction (MI) is a major cause of death and disability
worldwide. Despite advances in drug and device therapy, recovery of cardiac function and …